MAGIC Composite Score Predicts Outcomes of Second-Line Therapy for Acute GVHD

Area of Science:

• Hematology
• Immunology
• Oncology

Background:

• Acute graft-versus-host disease (GVHD) affects 30% of patients, with steroid-refractory cases having poor prognoses.
• Ruxolitinib is a standard treatment for steroid-refractory acute GVHD, but patient selection for optimal benefit remains unclear.

Purpose of the Study:

• To evaluate the performance of the MAGIC Composite Score (MCS) in predicting outcomes for patients initiating second-line treatment for acute GVHD.
• To assess if MCS can identify patients who do not benefit from ruxolitinib therapy.

Main Methods:

• The study analyzed data from 278 patients undergoing second-line treatment for acute GVHD.
• The MAGIC Composite Score (MCS), combining clinical symptoms and biomarkers, was used to stratify patients into risk groups.
• Outcomes including 1-year non-relapse mortality (NRM), 1-year survival, and day 28 complete response (CR) rates were assessed.

Main Results:

• MCS stratified patients into risk groups (MCS1-3), with 88% in intermediate or high-risk categories.
• Increasing MCS scores correlated with significantly higher 1-year NRM (16% to 73%), lower 1-year survival (77% to 24%), and lower day 28 CR rates (47% to 20%).
• MCS demonstrated superior prediction of 1-year NRM compared to clinical symptoms alone (AUROC 0.70 vs. 0.63). Patients with MCS2/3 scores had poor outcomes despite ruxolitinib treatment.

Conclusions:

• The MCS accurately predicts outcomes for acute GVHD patients requiring second-line therapy.
• MCS identifies patients with high NRM risk who may not benefit from current ruxolitinib treatment.
• MCS could serve as an eligibility criterion for future clinical trials in high-risk acute GVHD populations.